… differences or other environmental factors such as vitamin D levels and sun exposure. … G),
and acid hydrolases (cathepsin B and D). Autoantibodies may develop against any of these …

The coronavirus disease 2019 (COVID-19) pandemic has disproportionately affected
patients with kidney disease, causing significant challenges in disease management, kidney …

Background Cyclophosphamide and glucocorticoids have been the cornerstone of
remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)−associated …

Background The 18-month efficacy of a single course of rituximab as compared with conventional
immunosuppression with cyclophosphamide followed by azathioprine in patients with …

Human Parvovirus B19 (PV B19) is one of the several recently described ‘emerging viruses’
and has been identified as the etiological agent of ‘fifth disease’ in childhood. Human PV …

Objective To evaluate disease flare and postvaccination reactions (reactogenicity) in
patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV‐2 …

… Geetha b … fruit extract concentration [(a) 5 ml, (b) 7.5 ml, (c) 10 ml, (d) 12.5 ml, and (e) 15
ml]. … The average crystallite size calculated using Scherrer equation D = kλ/βcosθ with the …

An investigation on Fe-doped ZnO (Zn 1 − x Fe x O, x = 0, 0.03, 0.06 and 0.09 mM) nanopowder
have been synthesized by co-precipitated method annealed at 550 C were reported. …

Ni doped ZnO (Zn 1− x Ni x O, x = 0.0, 0.03, 0.06 and 0.09) nanorods have been synthesized
by Co-precipitation method. Zinc acetate dehydrate [Zn(CH 3 COO) 2 ⋅2H 2 O], nickel …

… Remission-induction regimens were RTX at 375 mg/m 2 × 4 or CYC at 2 mg/kg/d. CYC
was replaced by AZA (2 mg/kg/d) after 3–6 months. Both groups received glucocorticoids. …